Barinthus Biotherapeutics requests ADS listing withdrawal and trading suspension
Barinthus Biotherapeutics notified Nasdaq of voluntary ADS listing withdrawal tied to a Scheme of Arrangement and requested suspension before the market open on September 9, 2026. Nasdaq to file Form 25 to delist and deregister after effectiveness.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.